



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0


F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

LC20813c : Multiple lung cancer tissue array, including pathology grade, TNM and clinical stage, 192 cases/192 cores, replacing LC120813b

Microarray Panel	Multiple lung cancer tissue microarray, containing 72 cases of squamous cell carcinoma, 79 adenocarcinoma, 9 adenosquamous carcinoma, 21 small cell carcinoma, 3 atypical carcinoid, 2 sarcomatoid carcinoma, 1 each of pleomorphic carcinoma and adenocystic carcinoma, 4 mucoepidermoid carcinoma, single core per case	
Cores	192	LC20813c H&E 
Cases	192	
Row number	12	
Column number	16	
Core Diameter (mm)	1	
Thickness (µm)	5	
Tissue Array Type	FFPE	
Species	Human	
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.	
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, “**” means invalid core; “-” means no applicable or negative in IHC markers.	

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
B	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
C	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
D	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
E	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
F	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
G	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
H	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
I	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
J	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
K	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
L	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun

Legend: Lun - Lung

● - Malignant tumor, ● - Malignant tumor (stage IA), ● - Malignant tumor (stage IB), ● - Malignant tumor (stage IIA), ● - Malignant tumor (stage IIB), ● - Malignant tumor (stage IIIA), ● - Malignant tumor (stage IIIB), ● - Malignant tumor (stage IV)

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	72	M	Lung	Squamous cell carcinoma (fibrous tissue and... ood vessel)	T4N0M0	*	IIIA	Malignant	
A2	2	65	M	Lung	Squamous cell carcinoma	T3N0M0	1	IIB	Malignant	

A3	3	54	M	Lung	Squmous cell carcinoma	T1N0M0	2	IA	Malignant	
A4	4	63	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A5	5	61	F	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A6	6	51	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A7	7	73	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A8	8	69	M	Lung	Squmous cell carcinoma	T1N0M0	2	IA	Malignant	
A9	9	61	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A10	10	48	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A11	11	62	M	Lung	Squmous cell carcinoma	T2N1M0	2	IIA	Malignant	
A12	12	45	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A13	13	63	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A14	14	66	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
A15	15	67	M	Lung	Squmous cell carcinoma	T3N0M0	2	IIB	Malignant	
A16	16	50	F	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
B1	17	64	M	Lung	Squmous cell carcinoma	T3N0M0	2--3	IIB	Malignant	
B2	18	51	M	Lung	Squmous cell carcinoma	T3N1M0	2--3	IIIA	Malignant	
B3	19	70	F	Lung	Squmous cell carcinoma	T2N0M0	2--3	IB	Malignant	
B4	20	63	F	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
B5	21	45	M	Lung	Squmous cell carcinoma	T2N1M0	3	IIA	Malignant	
B6	22	55	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
B7	23	50	M	Lung	Squmous cell carcinoma	T2N1M0	3	IIA	Malignant	
B8	24	65	M	Lung	Squmous cell carcinoma	T4N0M0	3	IIIA	Malignant	
B9	25	43	F	Lung	Squmous cell carcinoma	T2N1M0	3	IIA	Malignant	
B10	26	46	M	Lung	Squmous cell carcinoma	T2N2M0	2	IIIA	Malignant	
B11	27	72	M	Lung	Squmous cell carcinoma	T2N1M0	3	IIA	Malignant	
B12	28	62	M	Lung	Squmous cell carcinoma	T2N1M0	3	IIA	Malignant	
B13	29	64	M	Lung	Squmous cell carcinoma	T3N1M1	3	IV	Malignant	
B14	30	56	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
B15	31	54	M	Lung	Squmous cell carcinoma	T3N0M0	3	IIB	Malignant	
B16	32	53	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C1	33	35	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C2	34	64	M	Lung	Squmous cell carcinoma	T3N2M0	3	IIIA	Malignant	
C3	35	76	M	Lung	Squmous cell carcinoma (necrosis)	T4N0M0	*	IIIA	Malignant	
C4	36	76	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C5	37	59	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C6	38	50	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C7	39	70	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C8	40	52	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C9	41	68	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C10	42	25	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C11	43	55	M	Lung	Squmous cell carcinoma	T2N1M0	2	IIA	Malignant	
C12	44	66	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C13	45	61	M	Lung	Squmous cell carcinoma	T4N0M0	3	IIIA	Malignant	
C14	46	39	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C15	47	60	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
C16	48	59	M	Lung	Squmous cell carcinoma (fibrous tissue and...ood vessel)	T2N0M0	*	IB	Malignant	
D1	49	62	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
D2	50	54	M	Lung	Squmous cell carcinoma (necrosis)	T2N2M0	*	IIIA	Malignant	
D3	51	76	M	Lung	Squmous cell carcinoma	T2N0M0	2	IB	Malignant	
D4	52	54	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
D5	53	49	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
D6	54	68	M	Lung	Squmous cell carcinoma with necrosis (spars e)	T4N1M0	3	IIIA	Malignant	
D7	55	66	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	
D8	56	52	M	Lung	Squmous cell carcinoma	T4N0M0	3	IIIA	Malignant	
D9	57	56	M	Lung	Squmous cell carcinoma	T2N0M0	3	IB	Malignant	

D10	58	55	F	Lung	Squamous cell carcinoma	T2N1M0	3	IIA	Malignant	
D11	59	48	M	Lung	Squamous cell carcinoma	T2N0M0	2	IB	Malignant	
D12	60	47	M	Lung	Squamous cell carcinoma	T2N0M0	3	IB	Malignant	
D13	61	71	M	Lung	Squamous cell carcinoma	T2N0M0	2	IB	Malignant	
D14	62	48	M	Lung	Squamous cell carcinoma	T2N0M0	3	IB	Malignant	
D15	63	57	M	Lung	Squamous cell carcinoma	T2N0M0	2	IB	Malignant	
D16	64	72	M	Lung	Squamous cell carcinoma	T2N0M0	2	IB	Malignant	
E1	65	55	M	Lung	Squamous cell carcinoma	T2N0M0	3	IB	Malignant	
E2	66	64	M	Lung	Squamous cell carcinoma	T2N0M0	3	IB	Malignant	
E3	67	67	M	Lung	Squamous cell carcinoma	T2N0M0	3	IB	Malignant	
E4	68	75	M	Lung	Squamous cell carcinoma	T3N0M0	3	IIB	Malignant	
E5	69	56	F	Lung	Squamous cell carcinoma	T4N0M0	3	IIIA	Malignant	
E6	70	77	M	Lung	Squamous cell carcinoma	T4N1M0	3	IIIA	Malignant	
E7	71	51	F	Lung	Squamous cell carcinoma	T4N0M0	3	IIIA	Malignant	
E8	72	64	M	Lung	Squamous cell carcinoma (sparse)	T4N0M0	3	IIIA	Malignant	
E9	73	57	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
E10	74	48	F	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
E11	75	69	M	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
E12	76	75	M	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
E13	77	55	F	Lung	Invasive adenocarcinoma	T2N1M0	2	IIA	Malignant	
E14	78	50	M	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
E15	79	64	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
E16	80	50	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
F1	81	59	M	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
F2	82	48	M	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
F3	83	39	M	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
F4	84	59	M	Lung	Invasive adenocarcinoma	T4N3M0	2	IIIB	Malignant	
F5	85	69	M	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
F6	86	62	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
F7	87	65	M	Lung	Invasive papillary adenocarcinoma	T2N0M0	-	IB	Malignant	
F8	88	56	F	Lung	Invasive papillary adenocarcinoma	T2N1M0	-	IIA	Malignant	
F9	89	82	M	Lung	Invasive adenocarcinoma (sparse)	T4N1M0	3	IIIA	Malignant	
F10	90	56	F	Lung	Invasive adenocarcinoma	T2N0M0	1--2	IB	Malignant	
F11	91	56	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
F12	92	60	M	Lung	Invasive papillary adenocarcinoma	T2N0M0	-	IB	Malignant	
F13	93	39	M	Lung	Invasive papillary adenocarcinoma	T4N0M0	-	IIIA	Malignant	
F14	94	49	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
F15	95	38	M	Lung	Invasive adenocarcinoma	T4N1M0	3	IIIA	Malignant	
F16	96	58	M	Lung	Invasive papillary adenocarcinoma	T2N0M0	-	IB	Malignant	
G1	97	55	M	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
G2	98	64	F	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
G3	99	64	F	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
G4	100	60	M	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
G5	101	53	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
G6	102	65	M	Lung	Invasive adenocarcinoma	T2N1M0	2	IIA	Malignant	
G7	103	52	F	Lung	Invasive adenocarcinoma	T1N0M0	2	IA	Malignant	
G8	104	53	F	Lung	Invasive papillary adenocarcinoma	T2N0M0	-	IB	Malignant	
G9	105	47	F	Lung	Invasive papillary adenocarcinoma	T3N1M0	-	IIIA	Malignant	
G10	106	71	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
G11	107	62	M	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
G12	108	54	F	Lung	Invasive adenocarcinoma	T4N1M0	3	IIIA	Malignant	
G13	109	61	F	Lung	Invasive papillary adenocarcinoma	T3N1M0	-	IIIA	Malignant	
G14	110	50	F	Lung	Invasive adenocarcinoma	T2N0M0	3	IB	Malignant	
G15	111	54	F	Lung	Invasive adenocarcinoma	T4N1M0	2	IIIA	Malignant	
G16	112	62	M	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	
H1	113	61	M	Lung	Invasive adenocarcinoma	T4N1M0	2	IIIA	Malignant	
H2	114	62	F	Lung	Invasive adenocarcinoma	T2N0M0	2	IB	Malignant	

K11	171	39	M	Lung	Small cell carcinoma	-	-	-	Malignant	
K12	172	47	M	Lung	Small cell carcinoma	-	-	-	Malignant	
K13	173	60	M	Lung	Small cell carcinoma	-	-	-	Malignant	
K14	174	31	F	Lung	Small cell carcinoma	-	-	-	Malignant	
K15	175	63	M	Lung	Small cell carcinoma	-	-	-	Malignant	
K16	176	66	M	Lung	Small cell carcinoma	-	-	-	Malignant	
L1	177	42	F	Lung	Small cell carcinoma	-	-	-	Malignant	
L2	178	58	M	Lung	Small cell carcinoma	-	-	-	Malignant	
L3	179	51	M	Lung	Small cell carcinoma	-	-	-	Malignant	
L4	180	64	M	Lung	Small cell carcinoma	-	-	-	Malignant	
L5	181	49	M	Lung	Atypical carcinoid	T4N2M0	-	IIIB	Malignant	
L6	182	60	M	Lung	Atypical carcinoid	T2N0M0	-	IB	Malignant	
L7	183	59	M	Lung	Atypical carcinoid	T2N0M0	-	IB	Malignant	
L8	184	47	M	Lung	Sarcomatoid carcinoma	T2N0M0	-	IB	Malignant	
L9	185	66	M	Lung	Pleomorphic carcinoma	T2N0M0	-	IB	Malignant	
L10	186	63	M	Lung	Sarcomatoid carcinoma	T2N1M0	-	IIA	Malignant	
L11	187	56	M	Lung	Mucoepidermoid carcinoma	T2N0M0	-	IB	Malignant	
L12	188	58	M	Lung	Mucoepidermoid carcinoma	T4N0M0	-	IIIA	Malignant	
L13	189	48	M	Lung	Mucoepidermoid carcinoma	T4N2M0	-	IIIB	Malignant	
L14	190	51	M	Lung	Mucoepidermoid carcinoma (lung tissue)	T4N1M0	*	IIIA	Malignant	
L15	191	67	M	Lung	Solid adenocarcinoma	T2M0N0	-	IB	Malignant	
L16	192	77	M	Lung	Adenocystic carcinoma	T1N0M0	-	IA	Malignant	
-	0									

The American Joint Committee on Cancer (AJCC) TNM system

T groups

TX: Primary tumor cannot be assessed

T0: No evidence of primary tumor

T1: A single tumor (any size) that hasn't grown into blood vessels

T2: Either a single tumor (any size) that has grown into blood vessels, OR more than one tumor where no tumor is larger than 5 cm (about 2 inches) across

T3a: Multiple tumors with at least one tumor that is greater than 5 cm (about 2 inches) across

T3b: At least one tumor (any size) that has grown into a major branch of the large veins of the liver (the portal and hepatic veins)

T4: The tumor has grown into a nearby organ (other than the gallbladder), OR the tumor is growing into the thin layer of tissue covering the liver (called the visceral peritoneum)

N groups

NX: Regional (nearby) lymph nodes cannot be assessed.

N0: The cancer has not spread to the regional lymph nodes.

N1: The cancer has spread to the regional lymph nodes.

M groups

M0: The cancer has not spread to distant lymph nodes or other organs.

M1: The cancer has spread to distant lymph nodes or other organs.



UK & Rest of the World
AMS Biotechnology (Europe) Ltd
184 Park Drive, Milton Park
Abingdon, OX14 4SE, UK
T: +44 (0)1235 828 200
F: +44 (0)1235 820 482



North America
amsbio LLC
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218



Germany
AMS Biotechnology (Europe) Ltd
Bockenheimer Landstr. 17/19
60325 Frankfurt/Main
T: +49 (0) 69 779099
F: +49 (0) 69 13376880



Switzerland
AMS Biotechnology (Europe) Ltd
Centro Nord-Sud 2E
CH-6934 Bioggio-Lugano
T: +41(0) 91 604 55 22
F: +41(0) 91 605 17 85